Chemical formula: C₂₇H₃₃NO₁₀S Molecular mass: 563.62 g/mol PubChem compound: 9915886
Thiocolchicoside interacts in the following cases:
Based on clinical experimentation, thiocolchicoside is used successfully and safely in combination with nonsteroidal anti-inflammatory drugs, phenylbutazone, analgesics and preparations used for the treatment of neuritis, anabolic steroids, sedatives, barbiturates and succinylcholine.
It is not recommended to use thiocolchicoside concomitantly with other medicines which have a muscle-relaxing effect on the muscular-skeletal system, as these may increase one another's impact. For the same reason, when thiocolchicoside is used with another medicine which produces effects on the smooth muscles, one should beware of a possible increase in the incidence rate of side effects, and ensure that the patient is monitored.
In a toxicity study on fertility in rats, no impairment of fertility was observed at doses up to 12 mg/kg, which matches dose levels with no clinical effect. Thiocolchicoside and its metabolites exert aneugenic activity at different dose levels, which is a risk factor for impairment of fertility in males.
In patients with epilepsy or seizure risks, as thiocolchicoside may predispose to seizures, it is recommended to evaluate the risk-benefit ratio of thiocolchicoside and to increase clinical monitoring. Any occurrence of seizures requires discontinuation of the treatment.
There is limited available data on the use of thiocolchicoside in pregnant women. As a result, the potential risks for the embryo and the foetus are unknown. Animal studies have shown teratogenic effects.
Thiocolchicoside is contra-indicated during pregnancy and in women of childbearing age who are not using contraceptives.
As thiocolchicoside passes into breast milk, its use is contra-indicated during breast-feeding.
In a toxicity study on fertility in rats, no impairment of fertility was observed at doses up to 12 mg/kg, which matches dose levels with no clinical effect. Thiocolchicoside and its metabolites exert aneugenic activity at different dose levels, which is a risk factor for impairment of fertility in males.
Clinical studies have not demonstrated any psychomotor impairments related to thiocolchicoside. However, drowsiness may commonly occur; this should be considered in vehicle drivers and machine operators.
Adverse events are classified per frequency as follows: Very Common (≥1/10), Common (≥1/100 and <1/10), Uncommon (≥1/1000 and <1/100), Rare (≥1/10000 and <1/1000), Very Rare (<1/10000), not known (cannot be estimated from the available data).
| Immune system disorders | |
| Rare: | Hypersensitivity reactions such as urticaria. |
| Frequency unknown: | Hypersensitivity reactions such as angioedema and, exceptionally, anaphylactic shock. |
| Frequency unknown: | Anaphylactic reactions. |
| Skin and subcutaneous tissue disorders | |
| Uncommon: | Skin reactions such as pruritus, erythema, maculopapular eruptions and, exceptionally, vesiculobullous eruptions. |
| Gastrointestinal disorders | |
| Common: | Diarrhoea, gastralgia. |
| Uncommon: | Nausea, vomiting. |
| Hepatobiliary disorders | |
| Frequency unknown: | Hepatic conditions (such as cytolytic or cholestatic hepatitis). |
| Nervous system disorders | |
| Common: | Drowsiness. |
| Frequency unknown: | Seizure or relapsed attack in epileptic patients. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.